Answers are grounded in this paper and cite their sources.
This review demonstrates the role of AI-assisted drug design in heterocyclic chemistry, highlighting advancements in machine learning and structural modeling to improve drug effectiveness and reduce R
Heterocyclic compounds form the backbone of a majority of clinically approved smallmolecule drugs due to their structural diversity, favorable physicochemical properties, and wide spectrum of biological activities. Despite their importance, conventional heterocyclic drug discovery remains a time-consuming and resourceintensive process, relying heavily on trial-and-error synthesis and extensive biological screening. In recent years, artificial intelligence (AI), particularly machine learning (ML), has emerged as a transformative approach in drug discovery, enabling rapid prediction of biological activity, toxicity, and pharmacokinetic behavior. This review critically examines the role of AI-assisted and fragment-based machine learning strategies in heterocyclic drug design. Special emphasis is placed on heterocycle-aware fragment representations, structure–activity relationship modeling, attention-based learning, and model interpretability. Current challenges, limitations, and future prospects of AI-driven heterocyclic medicinal chemistry are also discussed, highlighting the potential of these approaches to accelerate rational drug design and reduce attrition rates.
No takes yet. Share an insight, caveat, or question.
Anchal Sharma* Isha Sharma (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: